Role: Head of Lab
SCOPUS Author ID
Barbara Bottazzi is a Biologist working in Prof. Mantovani group since the beginning of her career, first at the Mario Negri Institute and then at the Istituto Clinico Humanitas. She spent several periods abroad, in Frederick (USA), in Oxford (UK) and in Cape Town (South Africa). She has been always involved in innate immunity. Initially she participates in the identification of MCP-1 as tumor-derived chemotactic factor involved in the recruitment of tumor-associated macrophages. In the last 20 years she deals with the long pentraxin PTX3, expressing the protein and characterizing the biochemical features of the molecule. She is currently involved in the clinical development of PTX3, both as a diagnostic and prognostic marker and as a possible therapeutic tool in selected human diseases. In recent years she has come back to address the relationship between inflammation and cancer, studying the role of a chemokine receptor in neoplastic transformation and characterizing new markers of tumor associated macrophages.
The Laboratory of Immunopharmacology is focused on soluble factors and cells involved in the innate immune response. A first interest is represented by the long pentraxin PTX3, a multifunctional molecule produced by stromal and immune cells involved in the response to selected pathogens. Since many years the Laboratory has been working on the biochemical and structural characterization of PTX3. In addition ongoing translational efforts are aimed at validate the use of PTX3 as diagnostic and prognostic marker in human pathology. A second field of interest concern tumor associated macrophages (TAM). Increasing evidences indicate that TAM can promote tumor growth and are associated to poor prognosis. Recently we found that TAM express an oncofetal truncated isoform of human fibronectin, called Migration Stimulating Factor (MSF). The Laboratory is involved in the generation of reagents (recombinant protein, antibodies) for the identification of MSF as possible marker of TAM and prognostic tool.
Bottazzi B, Fornasari L, Frangolho A, Giudicatti S, Mantovani A, Marabelli F, et al. Multiplexed label-free optical biosensor for medical diagnostics. Journal of biomedical optics. 2014;19(1):17006.
Beghe B, Verduri A, Bottazzi B, Stendardo M, Fucili A, Balduzzi S, et al. Echocardiography, spirometry, and systemic acute-phase inflammatory proteins in smokers with COPD or CHF: an observational study. PloS one. 2013;8(11):e80166.
Job ER, Bottazzi B, Short KR, Deng YM, Mantovani A, Brooks AG, et al. A single amino acid substitution in the hemagglutinin of H3N2 subtype influenza A viruses is associated with resistance to the long pentraxin PTX3 and enhanced virulence in mice. J Immunol. 2014;192(1):271-81.
Mantovani A, Valentino S, Gentile S, Inforzato A, Bottazzi B, Garlanda C. The long pentraxin PTX3: a paradigm for humoral pattern recognition molecules. Ann N Y Acad Sci. 2013;1285(1):1-14.
Latini R, Gullestad L, Masson S, Nymo SH, Ueland T, Cuccovillo I, et al. Pentraxin-3 in chronic heart failure: the CORONA and GISSI-HF trials. European journal of heart failure. 2012;14(9):992-9.
Knoflach M, Kiechl S, Mantovani A, Cuccovillo I, Bottazzi B, Xu Q, et al. Pentraxin-3 as a Marker of Advanced Atherosclerosis Results from the Bruneck, ARMY and ARFY Studies. PloS one. 2012;7(2):e31474.
Barbui T, Carobbio A, Finazzi G, Vannucchi AM, Barosi G, Antonioli E, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2011;96(2):315-8.
Inforzato A, Baldock C, Jowitt TA, Holmes DF, Lindstedt R, Marcellini M, et al. The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2. J Biol Chem. 2010;285(23):17681-92.
Deban L, Castro Russo R, Sironi M, Moalli F, Scanziani M, Zambelli V, et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol. 2010;11(4):328-34.
Bottazzi B, Doni A, Garlanda C, Mantovani A. An Integrated View of Humoral Innate Immunity: Pentraxins as a Paradigm. Annu Rev Immunol. 2010;28:157-83.